Phage Therapies Targeting Pathogenic Bacteria in Chronic Indications
Time: 1:00 pm
day: Day Two – Track A – 1
Details:
- BOLT – a novel phage discovery platform allowing clinical data within 12-18 months
- Cystic fibrosis – A phase 1b/2a study of BX004 targeting P. Aeruginosa
- Atopic dermatitis – BX005, a topical phage cocktail targeting S. Aureus
Speakers:
Assaf Oron has served as chief business officer since January 2017. Prior to this position, he served for over a decade at Evogene (NYSE:EVGN), an agriculture biotechnology company which utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. At Evogene, he worked in various roles such as executive vice president of…Read more